Note, certain items that must ship via Freight may not qualify for free shipping
Prevention and treatment of brain damage in streptozotocin induced diabetic rats with metformin, Nigella sativa , Zingiber officinale , and Punica granatum
S.MatarazzoF.StuartK

The full ingredient list: Ingredients: Aqua (Solvent), Tetrahexyldecyl Ascorbate (Antioxidant), Dimethicone (Skin conditioning agent), Glycerin (Humectant), C9-12 Alkane (Emollient), Ascorbyl Glucoside (Skin brightening agent, Silica (Opacifying agent), Pyrus Malus (Apple) Fruit Extract (Skin conditioning agent), Hydrogenated Lecithin (Skin conditioning agent), Polyglyceryl-6 polyricinoleate (Emollient), Mannitol (Skin conditioning agent), Sodium Hydroxide (Solvent), Acrylates/C10-30 Alkyl Acrylate Crosspolymer (Viscosity controlling agent), Xanthan Gum (Emulsion stabilizer), Glutathione (Antioxidant), Ergothioneine (Antioxidant), Oryza Sativa (Rice) Bran Extract (Skin conditioning agent), Hydroethyl Acrylate/Sodium Acryloylmethyl Taurate Copolymer (Dispersing agent), Cetyl Alcohol (Emulsion stabilizer), Caprylyl Glycol (Skin conditioning agent), Lysine Carboxymethyl Cysteinate (Skin conditioning agent), Coco-Caprylate/Caprate (Skin conditioning agent), Tocopherol (Skin conditioning agent), Sodium Citrate (pH adjuster), Sodium Phytate (Chelating agent), Hexylene Glycol (Emulsifier), Ethylhexylglycerin (Skin conditioning agent), Helianthus Annuus (Sunflower) Extract (Emollient), Urea (Humectant), Caprylic/Capric Triglyceride (Skin conditioning agent), Sodium PCA (Skin conditioning agent), Rosmarinus Officinalis (Rosemary) Leaf Extract (Skin conditioning agent), Polysorbate 60 (Surfactant), Sorbitan Isostearate (Surfactant), Trehalose (Humectant), Ascorbic Acid (Skin conditioning agent), Glucose (Solvent), Vanilla Planifolia Fruit Extract (Skin conditioning agent), Polyquaternium-51 (Humectant), Triacetin (Solvent), Sodium Hyaluronate (Skin conditioning agent), Phenoxyethanol (Preservative)

Nutrients 13 (7), 2327
As with much of the rare disease field, rare vascular disease trials face the same structural challenge: patient populations are small and scattered across countries, making cross-border collaboration essential rather than optional